Oncotarget

Meta-Analysis:

The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials

Bum Jun Kim, Jae Ho Jeong, Hyeong Su Kim and Jung Han Kim _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102371-102380. https://doi.org/10.18632/oncotarget.21987

Metrics: PDF 824 views  |   HTML 1068 views  |   ?  


Abstract

Bum Jun Kim1,2,*, Jae Ho Jeong3,*, Hyeong Su Kim1 and Jung Han Kim1

1Division of Hemato-Oncology, Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea

2Division of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam, Republic of Korea

3Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

*These authors contributed equally to this work

Correspondence to:

Jung Han Kim, email: harricil@hotmail.com, harricil@hallym.or.kr

Keywords: head and neck cancer, anti-EGFR agents, cetuximab, meta-analysis

Received: July 23, 2017     Accepted: September 25, 2017     Published: October 20, 2017

ABSTRACT

There has been a debate over whether the addition of anti-epidermal growth factor receptor (EGFR) agents to the conventional treatments has beneficial effects in patients with head and neck squamous cell carcinoma (HNSCC). This meta-analysis was performed to investigate the role of anti-EGFR agents in patients with locoregionally advanced HNSCC (LA-HNSCC). A systematic search of the electronic databases was carried out. From eight randomized controlled trials, 2,263 patients were included in the meta-analysis. Compared with chemoradiotherapy (CRT), the addition of an EGFR inhibitor to radiotherapy (RT) or CRT did not improve locoregional control (hazard ratio (HR) = 1.19 [95% confidence interval (CI): 0.99–1.42], P = 0.06), progression-free survival (HR = 1.07 [95% CI: 0.92–1.24], P = 0.37), and overall survival (HR = 1.04 [95% CI, 0.88–1.23], P = 0.65) in patients with LA-HNSCC. Moreover, the addition of anti-EGFR agents increased the risk of skin toxicities (odds ratio = 4.04 [95% CI: 2.51–6.48], P < 0.00001) and mucositis (odds ratio = 1.58 [95% CI: 0.99–2.52], P = 0.06). In conclusion, this meta-analysis indicates that the addition of an anti-EGFR agent to RT or CRT do not improve clinical outcomes compared with CRT in patients with LA-HNSCC. Except for patients with coexisting medical conditions or decreased performance status, concurrent CRT should remain the standard of care for patients with LA-HNSCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21987